{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:34:24Z","timestamp":1782603264934,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12028-019-00850-0","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T02:10:21Z","timestamp":1569895821000},"page":"348-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reversible Cerebral Vasoconstriction Syndrome Responsive to Intravenous Milrinone"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5431-1651","authenticated-orcid":false,"given":"Maximiliano A.","family":"Hawkes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A.","family":"Hlavnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor A.","family":"Wainsztein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"issue":"10","key":"850_CR1","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S1474-4422(12)70135-7","volume":"11","author":"A Ducros","year":"2012","unstructured":"Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11(10):906\u201317. \nhttps:\/\/doi.org\/10.1016\/S1474-4422(12)70135-7\n\n.","journal-title":"Lancet Neurol"},{"issue":"6","key":"850_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11940-017-0460-7","volume":"19","author":"C Cappelen-Smith","year":"2017","unstructured":"Cappelen-Smith C, Calic Z, Cordato D. Reversible cerebral vasoconstriction syndrome: recognition and treatment. Curr Treat Options Neurol. 2017;19(6):21. \nhttps:\/\/doi.org\/10.1007\/s11940-017-0460-7\n\n.","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"850_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1055\/s-0032-1331812","volume":"32","author":"S Purkayastha","year":"2012","unstructured":"Purkayastha S, Sorond F. Transcranial Doppler ultrasound: technique and application. Semin Neurol. 2012;32(4):411\u201320. \nhttps:\/\/doi.org\/10.1055\/s-0032-1331812\n\n.","journal-title":"Semin Neurol"},{"issue":"3","key":"850_CR4","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12028-012-9685-1","volume":"16","author":"C Lazaridis","year":"2012","unstructured":"Lazaridis C, Czosnyka M. Cerebral blood flow, brain tissue oxygen, and metabolic effects of decompressive craniectomy. Neurocrit Care. 2012;16(3):478\u201384. \nhttps:\/\/doi.org\/10.1007\/s12028-012-9685-1\n\n.","journal-title":"Neurocrit Care"},{"key":"850_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21951","author":"S-P Chen","year":"2009","unstructured":"Chen S-P, Fuh J-L, Wang S-J, et al. Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol. 2009. \nhttps:\/\/doi.org\/10.1002\/ana.21951\n\n.","journal-title":"Ann Neurol"},{"issue":"3","key":"850_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jamaneurol.2013.5875","volume":"71","author":"A Ducros","year":"2014","unstructured":"Ducros A, Hajj-Ali RA, Singhal AB, Wang S-J. Reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2014;71(3):368. \nhttps:\/\/doi.org\/10.1001\/jamaneurol.2013.5875\n\n.","journal-title":"JAMA Neurol"},{"issue":"10","key":"850_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1586\/erc.10.124","volume":"8","author":"A Sattar","year":"2010","unstructured":"Sattar A, Manousakis G, Jensen MB. Systematic review of reversible cerebral vasoconstriction syndrome. Expert Rev Cardiovasc Ther. 2010;8(10):1417\u201321. \nhttps:\/\/doi.org\/10.1586\/erc.10.124\n\n.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"2","key":"850_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamaneurol.2015.3472","volume":"73","author":"DM Sorensen","year":"2016","unstructured":"Sorensen DM. Reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2016;73(2):232\u20133. \nhttps:\/\/doi.org\/10.1001\/jamaneurol.2015.3472\n\n.","journal-title":"JAMA Neurol"},{"issue":"3","key":"850_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1212\/WNL.0000000000003510","volume":"88","author":"AB Singhal","year":"2017","unstructured":"Singhal AB, Topcuoglu MA. Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome. Neurology. 2017;88(3):228\u201336. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000003510\n\n.","journal-title":"Neurology"},{"issue":"8","key":"850_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/archneurol.2011.68","volume":"68","author":"AB Singhal","year":"2011","unstructured":"Singhal AB, Hajj-Ali RA, Topcuoglu MA, et al. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol. 2011;68(8):1005\u201312. \nhttps:\/\/doi.org\/10.1001\/archneurol.2011.68\n\n.","journal-title":"Arch Neurol"},{"issue":"Pt 12","key":"850_CR11","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1093\/brain\/awm256","volume":"130","author":"A Ducros","year":"2007","unstructured":"Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser M-G. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007;130(Pt 12):3091\u2013101. \nhttps:\/\/doi.org\/10.1093\/brain\/awm256\n\n.","journal-title":"Brain"},{"issue":"12","key":"850_CR12","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1212\/01.wnl.0000249115.63436.6d","volume":"67","author":"S-P Chen","year":"2006","unstructured":"Chen S-P, Fuh J-L, Lirng J-F, Chang F-C, Wang S-J. Recurrent primary thunderclap headache and benign CNS angiopathy: spectra of the same disorder? Neurology. 2006;67(12):2164\u20139. \nhttps:\/\/doi.org\/10.1212\/01.wnl.0000249115.63436.6d\n\n.","journal-title":"Neurology"},{"issue":"2","key":"850_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000447626","volume":"8","author":"EB Marsh","year":"2016","unstructured":"Marsh EB, Ziai WC, Llinas RH. The need for a rational approach to vasoconstrictive syndromes: transcranial doppler and calcium channel blockade in reversible cerebral vasoconstriction syndrome. Case Rep Neurol. 2016;8(2):161\u201371. \nhttps:\/\/doi.org\/10.1159\/000447626\n\n.","journal-title":"Case Rep Neurol"},{"issue":"1","key":"850_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.7326\/0003-4819-146-1-200701020-00007","volume":"146","author":"LH Calabrese","year":"2007","unstructured":"Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146(1):34\u201344.","journal-title":"Ann Intern Med"},{"issue":"1","key":"850_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamaneurol.2013.4639","volume":"71","author":"BS Katz","year":"2014","unstructured":"Katz BS, Fugate JE, Ameriso SF, et al. Clinical worsening in reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2014;71(1):68\u201373. \nhttps:\/\/doi.org\/10.1001\/jamaneurol.2013.4639\n\n.","journal-title":"JAMA Neurol"},{"issue":"6","key":"850_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1468-2982.2008.01768.x","volume":"29","author":"M Elstner","year":"2009","unstructured":"Elstner M, Linn J, Muller-Schunk S, Straube A. Reversible cerebral vasoconstriction syndrome: a complicated clinical course treated with intra-arterial application of nimodipine. Cephalalgia. 2009;29(6):677\u201382. \nhttps:\/\/doi.org\/10.1111\/j.1468-2982.2008.01768.x\n\n.","journal-title":"Cephalalgia"},{"issue":"10","key":"850_CR17","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1177\/0333102410394673","volume":"31","author":"J Linn","year":"2011","unstructured":"Linn J, Fesl G, Ottomeyer C, et al. Intra-arterial application of nimodipine in reversible cerebral vasoconstriction syndrome: a diagnostic tool in select cases? Cephalalgia. 2011;31(10):1074\u201381. \nhttps:\/\/doi.org\/10.1177\/0333102410394673\n\n.","journal-title":"Cephalalgia"},{"issue":"1","key":"850_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1526-4610.2008.01211.x","volume":"49","author":"M Bouchard","year":"2009","unstructured":"Bouchard M, Verreault S, Gariepy J-L, Dupre N. Intra-arterial milrinone for reversible cerebral vasoconstriction syndrome. Headache. 2009;49(1):142\u20135. \nhttps:\/\/doi.org\/10.1111\/j.1526-4610.2008.01211.x\n\n.","journal-title":"Headache"},{"issue":"12","key":"850_CR19","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s00234-003-1129-3","volume":"46","author":"JK Song","year":"2004","unstructured":"Song JK, Fisher S, Seifert TD, et al. Postpartum cerebral angiopathy: atypical features and treatment with intracranial balloon angioplasty. Neuroradiology. 2004;46(12):1022\u20136. \nhttps:\/\/doi.org\/10.1007\/s00234-003-1129-3\n\n.","journal-title":"Neuroradiology"},{"issue":"4","key":"850_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/02688697.2018.1479512","volume":"32","author":"F Al-Mufti","year":"2018","unstructured":"Al-Mufti F, Dodson V, Wajswol E, et al. Chemical angioplasty for medically refractory reversible cerebral vasoconstriction syndrome(). Br J Neurosurg. 2018;32(4):431\u20135. \nhttps:\/\/doi.org\/10.1080\/02688697.2018.1479512\n\n.","journal-title":"Br J Neurosurg"},{"issue":"3","key":"850_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1161\/STROKEAHA.107.492447","volume":"39","author":"AT Fraticelli","year":"2008","unstructured":"Fraticelli AT, Cholley BP, Losser M-R, Saint Maurice J-P, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39(3):893\u20138. \nhttps:\/\/doi.org\/10.1161\/STROKEAHA.107.492447\n\n.","journal-title":"Stroke"},{"issue":"3","key":"850_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s12028-012-9701-5","volume":"16","author":"M Lannes","year":"2012","unstructured":"Lannes M, Teitelbaum J, del Pilar Cortes M, Cardoso M, Angle M. Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol. Neurocrit Care. 2012;16(3):354\u201362. \nhttps:\/\/doi.org\/10.1007\/s12028-012-9701-5\n\n.","journal-title":"Neurocrit Care"},{"key":"850_CR23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jns.2017.08.1808","volume":"381","author":"N Oyama","year":"2017","unstructured":"Oyama N, Sakaguchi M, Higashida K, et al. Remarkable effect of a phosphodiesterase type 3 inhibitor, milrinone in a reversible cerebral vasoconstriction syndrome patient with ischemic stroke: a case report. J Neurol Sci. 2017;381:642. \nhttps:\/\/doi.org\/10.1016\/j.jns.2017.08.1808\n\n.","journal-title":"J Neurol Sci"},{"key":"850_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jns.2018.12.027","volume":"397","author":"K Lakhal","year":"2019","unstructured":"Lakhal K, Rodie-Talbere P-A, Alexandre P-L, Testard N, Rozec B, Daumas-Duport B. Continuous intravenous milrinone for severe reversible cerebral vasoconstriction syndrome (a case report). J Neurol Sci. 2019;397:55\u20137. \nhttps:\/\/doi.org\/10.1016\/j.jns.2018.12.027\n\n.","journal-title":"J Neurol Sci"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-019-00850-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12028-019-00850-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-019-00850-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T23:52:36Z","timestamp":1601337156000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12028-019-00850-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1007\/s12028-019-00850-0","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"30 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}